title: A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis.
abstract: Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy. While biologic agents used to treat moderate-to-severe psoriasis, such as tumor necrosis factor-α inhibitors and interleukin-17 inhibitors, are known to increase patients' risk of developing localized candidiasis, the overall risk of infection is low, and candidiasis can be effectively managed in most patients while receiving systemic psoriasis therapies. Thus, the development of candidiasis does not usually necessitate changes to psoriasis treatment regimens.
authors.affiliation: Keck School of Medicine, University of Southern California, 1975 Zonal Avenue, Keith Administration Building, Room 510, Los Angeles, CA, 90089, USA. aprilarmstrong@post.harvard.edu.
authors.forename: April W
authors.initials: AW
authors.lastname: Armstrong
authors.affiliation: Altman Dermatology Associates, Arlington Heights, IL, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Bukhalo
authors.affiliation: Oregon Medical Research Center, Portland, OR, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Blauvelt
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D003937:Diagnosis, Differential; D006801:Humans; D020381:Interleukin-17 / Q000502:physiology; D011565:Psoriasis / Q000382:microbiology*; D012720:Severity of Illness Index
chemical_list: D000935:Antifungal Agents; D020381:Interleukin-17